The disclosed invention relates to a chemical composition that can be taken orally and supplements an unhealthy diet and lifestyle. In one aspect of the invention the chemical composition includes Retinol Palmitate, Thiamine, Riboflavin, Niacin, Nicotinamide mononucleotide (NMN), Pyridoxal, Folic Acid, Cyanocobalamin, Cholecalciferol, Zinc, Manganese, Copper, Calcium, Magnesium, Iron, L-Selenomethionine, Lysine, Phenylalanine, L-Threonine, L-Methionine, L-Histidine, L-Tryptophan, L-Leucine, L-Isoleucine, L-Valine, Cinnamon Bark Powder, and Curcumin.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

The present invention generally relates to supplement compositions for patients receiving current or chronic nitrous oxide treatment.

The present invention generally relates to supplement compositions for patients receiving current or chronic nitrous oxide treatment.

The present invention relates to a solid oral dosage form comprising naproxen and vitamin B6. Preferably, it is a solid oral dosage form for use in the treatment of pain such as low back pain. It is a fixed-dose combination (FDC) which increases patient compliance. The method of preparing such solid oral dosage form comprises the extragranular addition of vitamin B6 to an intragranular composition, wherein said intragranular composition comprises naproxen or a pharmaceutically acceptable salt thereof and at least one binder.

The present invention relates to a solid oral dosage form comprising naproxen and vitamin B6. Preferably, it is a solid oral dosage form for use in the treatment of pain such as low back pain. It is a fixed-dose combination (FDC) which increases patient compliance. The method of preparing such solid oral dosage form comprises the extragranular addition of vitamin B6 to an intragranular composition, wherein said intragranular composition comprises naproxen or a pharmaceutically acceptable salt thereof and at least one binder.

The present invention relates generally to the field of insulin sensitizers. In particular, the present invention relates to scyllo-inositol for use as an insulin sensitizer in the treatment or prevention of hyperglycemia. The present invention further relates to scyllo-inositol for use as an insulin sensitizer in the treatment or prevention of disorders, conditions, and/or symptoms associated with hyperglycemia in a subject.

The present invention relates generally to the field of insulin sensitizers. In particular, the present invention relates to scyllo-inositol for use as an insulin sensitizer in the treatment or prevention of hyperglycemia. The present invention further relates to scyllo-inositol for use as an insulin sensitizer in the treatment or prevention of disorders, conditions, and/or symptoms associated with hyperglycemia in a subject.